Zhou, Lijie http://orcid.org/0000-0002-2425-6946
Du, Kaixuan
Dai, Yiheng
Zeng, Youmiao
Luo, Yongbo
Ren, Mengda
Pan, Wenbang
Liu, Yuanhao
Zhang, Lailai
Zhu, Ronghui
Feng, Dapeng
Tian, Fengyan
Gu, Chaohui
Funding for this research was provided by:
National Natural Science Foundation of China (NO. 82203099, NO. 82173294)
Article History
Received: 20 November 2023
Accepted: 6 January 2024
First Online: 13 January 2024
Declarations
:
: Not applicable.
: The subcutaneous xenograft model was agreed by the Ethics Committee of Experimental Animal Center of Zhengzhou University. Male BALB/c nude mice (approximately 4 weeks old), purchased from Beijing Weitong Lihua Experimental Animal Technology, were divided into 8 groups with 5 mice per subgroup. Four groups be used for studying the effect of FASN knockdown on the reversal of gemcitabine resistance induced in vivo: Group I (DMSO: DMSO), group II (DMSO: gemcitabine), group III (FASN knockdown: DMSO) and group IV (FASN knockdown: gemcitabine). Four groups be used for studying the effect of TVB-3166 on the reversal of gemcitabine resistance in vivo: Group I (DMSO: DMSO), group II (DMSO: gemcitabine), group III (DMSO: TVB-3166) and group IV (gemcitabine: TVB-3166). In this experiment, 2*10<sup>6</sup> BLCA cells were injected subcutaneously into each mouse. After that, the volume of the tumor was recorded every 5 days. Drug therapy was initiated when the average tumor size was measured at 100–200 mm<sup>3</sup>.After 50 days, we removed the subcutaneous tumor from the mice. After measurement and recording, we partially stored these tumors at in a − 80 °C freezer and partially embedded them in paraffin. Mice treated with gemcitabine were intraperitoneally injected with gemcitabine 50 mg/kg every 2 days. Mice treated with TVB-3166 were intragastrically administered 60 mg/kg TVB-3166 daily for approximately 5 weeks.
: All authors agree to publish.
: All the authors declared that they had no competing interests.